Actavis PLC (ACT.N)
25 Jul 2014
|Market Cap (Mil.):||$57,640.67|
|Shares Outstanding (Mil.):||265.08|
WASHINGTON - Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.
(Adds details of drugs to be divested, share price, other pharma deals)
WASHINGTON, June 30 - Pharmaceutical company Actavis Plc has won U.S. approval to buy Forest Laboratories on condition that it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.
June 26 - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda's multiple sclerosis treatment, Ampyra.
June 23 - Forest Laboratories Inc, which is being acquired by generic drugmaker Actavis Plc, said on Monday that its antidepressant Viibryd performed significantly better than a placebo for treating generalized anxiety disorder, according to data from three late-stage studies.
BRIEF-U.S. appeals court rules for Novartis, Actavis, Apotex and against Allergan, Duke over patents related to eyelash growth
June 10 - Novartis AG : * Actavis PLC apotex inc win reversal of lower court ruling regarding
(The following statement was released by the rating agency) CHICAGO, June 10 (Fitch) Fitch Ratings has assigned a 'BBB-' rating to new senior unsecured bonds to be issued by an indirect subsidiary of Actavis plc (NYSE: ACT). Fitch has also assigned a 'BBB-' Issuer Default Rating (IDR) to Actavis Funding SCS, the issuer of the bonds, and Warner Chilcott Limited. ACT's IDR is 'BBB-', with a Stable Outlook. A full list of ratings for ACT follows at the end of this release. The new unsecured no
WASHINGTON - Forest Laboratories Inc, which itself is in the process of being acquired, has won U.S. antitrust approval to buy Furiex Pharmaceuticals Inc, the Federal Trade Commission said on Friday.
LONDON - Eli Lilly and Co LLY.N has lost a patent case in the English High Court over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis Plc ACT.N, dealing a blow to the U.S. drugmaker's future sales hopes.
* UK court rules Actavis can launch generic version of drug